We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generics Continue Push for More Transparency in 180-Day Market Exclusivity Decisions
Generics Continue Push for More Transparency in 180-Day Market Exclusivity Decisions
The FDA should make its consideration of ANDA first-filer status a far more public process, say generics firms that continue to seek more transparency and communications from the agency in general on the generic drug application process.